We also found that in ovarian cancer and non-small cell lung cancer, PRMT5 inhibition in combination with PARP inhibitors acted synergistically, with a stronger killing effect on tumor cells and even re-sensitizing resistant ovarian cancer cells to PARP inhibitors [109]. Here, PRMT5 is linked to neoplasm.